Gland Pharma Limited

rs 25

IMITED February 14, 2024 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 Dear Sir/Madam, National Stock Exch

85%

n) Gross Profit (1) / Gross Profit Margin (2) (INR Mn / %) 41,273 28,396 13,734 15,452 9,383 85% 8,519 62% 5,112 54% 15,190 53% 9,459 61% 25,536 62% Q3 FY23 Q2 FY24 Q3 FY24 9M FY23

62%

ofit (1) / Gross Profit Margin (2) (INR Mn / %) 41,273 28,396 13,734 15,452 9,383 85% 8,519 62% 5,112 54% 15,190 53% 9,459 61% 25,536 62% Q3 FY23 Q2 FY24 Q3 FY24 9M FY23 9M FY24 Q3

54%

ross Profit Margin (2) (INR Mn / %) 41,273 28,396 13,734 15,452 9,383 85% 8,519 62% 5,112 54% 15,190 53% 9,459 61% 25,536 62% Q3 FY23 Q2 FY24 Q3 FY24 9M FY23 9M FY24 Q3 FY23 Q2 FY2

53%

argin (2) (INR Mn / %) 41,273 28,396 13,734 15,452 9,383 85% 8,519 62% 5,112 54% 15,190 53% 9,459 61% 25,536 62% Q3 FY23 Q2 FY24 Q3 FY24 9M FY23 9M FY24 Q3 FY23 Q2 FY24 Q3 FY24 9

61%

NR Mn / %) 41,273 28,396 13,734 15,452 9,383 85% 8,519 62% 5,112 54% 15,190 53% 9,459 61% 25,536 62% Q3 FY23 Q2 FY24 Q3 FY24 9M FY23 9M FY24 Q3 FY23 Q2 FY24 Q3 FY24 9M FY23 9M F

11%

9M FY23 9M FY24 EBITDA (3) / EBITDA Margin (4) (INR Mn / %) PAT / PAT Margin (5) (INR Mn / %) 11% 8,563 30% 9,744 24% 2,896 31% 3,205 23% 3,557 23% 27% 2,319 25% -1% 17% 1,941 14%

30%

M FY24 EBITDA (3) / EBITDA Margin (4) (INR Mn / %) PAT / PAT Margin (5) (INR Mn / %) 11% 8,563 30% 9,744 24% 2,896 31% 3,205 23% 3,557 23% 27% 2,319 25% -1% 17% 1,941 14% 1,919 12%

24%

DA (3) / EBITDA Margin (4) (INR Mn / %) PAT / PAT Margin (5) (INR Mn / %) 11% 8,563 30% 9,744 24% 2,896 31% 3,205 23% 3,557 23% 27% 2,319 25% -1% 17% 1,941 14% 1,919 12% 7,024 25%

31%

TDA Margin (4) (INR Mn / %) PAT / PAT Margin (5) (INR Mn / %) 11% 8,563 30% 9,744 24% 2,896 31% 3,205 23% 3,557 23% 27% 2,319 25% -1% 17% 1,941 14% 1,919 12% 7,024 25% 5,800 14%

23%

4) (INR Mn / %) PAT / PAT Margin (5) (INR Mn / %) 11% 8,563 30% 9,744 24% 2,896 31% 3,205 23% 3,557 23% 27% 2,319 25% -1% 17% 1,941 14% 1,919 12% 7,024 25% 5,800 14% Q3 FY23 Q2

27%

PAT / PAT Margin (5) (INR Mn / %) 11% 8,563 30% 9,744 24% 2,896 31% 3,205 23% 3,557 23% 27% 2,319 25% -1% 17% 1,941 14% 1,919 12% 7,024 25% 5,800 14% Q3 FY23 Q2 FY24 Q3 FY24 9

“There will be a temporary supply disruption from this line; however, all the facility's other lines will remain operational.”

Corporate Office

2

Regd. Office

1

Regd. Office

Survey N o . 143-148, 1 5 0 & 151, N e a r Gandimaisamma 'X' Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043,Telangana, India Tel: +91-40-30510999 Fax: + 9 1 0-30510800

Corporate Office

Plot N o . 11 & 84, T S I I C Phase: I V Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLAND PHARMA LIMITED Gland Pharma Limited Financial Results Q3’FY24 14th February 2024 Cemcitibii lajectiM ■ Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from thes

Corporate Office

Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India B S E 543245 ®NSE GLAND Bloomberg GLAND:IN 13